The DOI matches its Crossref record; 191 of the 193 references it cites were found in a registry or an index.
General aspects of neurodegeneration
Abstract
Neurodegenerative diseases are morphologically featured by progressive cell loss in specific vulnerable neuronal populations of the central nervous system, often associated with cytoskeletal protein aggregates forming intracytoplasmic and/or intranuclear inclusions in neurons and/or glial cells. Most neurodegenerative disorders are now classified either according to the hitherto known genetic mechanisms or to the major components of their cellular protein inclusions. The major basic processes inducing neurodegeneration are considered multifactorial ones caused by genetic, environmental, and endogenous factors. They include abnormal protein dynamics with defective protein degradation and aggregation, many of them related to the ubiquitin-proteasomal system, oxidative stress and free radical formation, impaired bioenergetics and mitochondrial dysfunctions, and "neuroinflammatory" processes. These mechanisms that are usually interrelated in complex vitious circles finally leading to programmed cell death cascades are briefly discussed with reference to their pathogenetic role in many, albeit diverse neurodegenerative diseases, like Alzheimer disease, synucleinopathies, tauopathies, and polyglutamine disorders. The impact of protein inclusions on cell dysfunction, activation or prevention of cell death cascades are discussed, but the molecular basis for the underlying disease mechanisms remains to be elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A strong argument in favor of complex pharmacology strategies for the treatment of complex neurodegenerative diseases is based on the fact that these diseases are multifactorial, that is, they are caused by multiple factors, being possibly genetic, environmental, endogenous, or even having more than one factor operating at the same time.21”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [21]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Mechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,209
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174
A Drosophila model of Parkinson's disease
Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,156
Aggresomes, inclusion bodies and protein aggregation
Kopito, R. R. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01852-3 · Cited by 1,942
Flagged first, then by citations
2 of the 193 references couldn’t be matched to a known paper.
Research works printed but not linked: 19
- Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552–1555 · DOI
- Cluskey S, Ramsden DB (2001) Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol 54: 386–392
- Henry JM, Jellinger KA (2003) Postencephalitic parkinsonism. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- Jellinger KA (2003b) Experimental models of synucleinopathies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- Jellinger KA, Duda J (2003) Neuroaxonal dystrophies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- Jellinger KA, Mizuno Y (2003) Parkinson disease. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- Lantos PL, Quinn N (2003) Dementia with Lewy bodies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- Linert W, Jellinger KA (2001) Cell death mechanisms and the role of iron in neurodegeneration. In: Segura-Aquilar J (ed) Mechanisms of degeneration and protection of the dopaminergic system. FP Graham Publishing, Johnson City, pp 21–65
- Lippa CF (2003) Lewy bodies in conditions other than disorders of α-synuclein. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- McGeer PL, McGeer EG (2002) Polymorphisms in inflammatory genes enhance the risk of Alzheimer disease. Alzheimer Research Forum, February 11, 2002
- Merlini G, Bellotti V, Andreola A, Palladini G, Obici L, Casarini S, Perfetti V (2001) Protein aggregation. Clin Chem Lab Med 39: 1065–1075
- Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS (2000) Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 47: 365–368 · DOI
- Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090–3099 · DOI · Paper page
- Perry G, Liu Q, Wataya T, Shimohama S, Nunomura A, Siedlak SL, Sayre LL, Smith MA (2002) Neurofilament proteins are major targets of oxidative damage in the nervous system. J Neuropathol Exp Neurol 61: 456
- Perry G, Srinivas R, Nunomura A, Smith MA (2003) Oxidative mechanisms in neurodegenerative diseases. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
- Perry G, Zhu X, Atwood CS, Numamura A, Smith MA (2002) Oxidative abnormalities as a window to Alzheimer disease. 8th International Conference on Alzheimer disease and Related Disorders, July 19–25, 2002, Abstr. # 4235
- Simon DK, Beal MF (2002) Pathogenesis: oxidative stress, mitochondrial dysfunction and excitotoxicity. In: Factor SA, Weiner WJ (eds) Parkinson’s disease. Diagnosis and management. Demos, New York, pp 281–290
- Tatton WG, Olanow CW (1999) Apoptosis in neurodegenerative disease: The role of mitochondria. Biochem Biophys Acta 1410: 195–214
- Trojanowski J (2003) Protein aggregation. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
Cited by
Sorted by citations
Items 101–132 of 132
Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design
Bolognesi, M. L., Melchiorre, C., der Schyf, C. J. V., & Youdim, M. B. H. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00290 · Cited by 3
Nakajima, M. (2004) · The Japan Journal of Logopedics and Phoniatrics · doi:10.5112/jjlp.45.309 · Cited by 3
Stem Cells and Natural Agents in the Management of Neurodegenerative Diseases: A New Approach
Brockmueller, A., Mahmoudi, N., Moaveni, A. K., Mueller, A., Kajbafzadeh, A. M., Shakibaei, M., & Zolbin, M. M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03746-2 · Cited by 2
Oxidative stress in Alzheimer's disease: the role of vitamins C and E.
Cardoso, B. R., & Cozzolino, S. M. F. (2009) · Cited by 2
Clinical Bioenergetics: Understanding the Interplay Between Energy Metabolism and Human Health
Ostojić, S. M. (2024) · Clinical bioenergetics · doi:10.3390/clinbioenerg1010001 · Cited by 1
New Synthons of 3-Hydroxyquinoline Derivatives Through SEAr
Massoud, M. A. M., Bialy, S. A. A. E., Bayoumi, W. A., & Husseiny, W. M. E. (2014) · Letters in Organic Chemistry · doi:10.2174/157017861109140903105543 · Cited by 1
14 Neurodegenerative Erkrankungen – eine Anti-Aging-Herausforderung
(2005) · Thieme eBooks · doi:10.1055/b-0034-23265 · Cited by 1
Fernández-Fernández, L., Solé, M., Bolea, I., Valente, T., Serrano, J. C. E., Jové, M., Ramírez, B., Anglès, N., Reguant, J., Morelló, J. R., et al. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00078-1 · Cited by 1
Methylmercury and Alzheimer’s Disease
Nabi, S. (2014) · Springer eBooks · doi:10.1007/978-81-322-1922-4_26 · Cited by 1
Advanced prodrug approaches for neurodegenerative diseases
Raju, R., Nayak, A., Das, P., Gajmer, A., Ramya, A., & Tejaswini, R. (2023) · Brazilian Journal of Science · doi:10.14295/bjs.v2i10.369 · Cited by 1
Vishnumurthy, R. H., Priya, M. G. R., Tiwari, P. K., & Solomon, V. R. (2024) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024060189 · Cited by 1
Direct- And Spacer-Coupled Codrug Strategies for the Treatment of Alzheimer's Disease
Fornasari, E., Stefano, V. D., & Cacciatore, I. (2014) · Cited by 1
Protective and Regenerative Autoimmunity in CNS Injury
Kipnis, J., & Schwartz, M. (2008) · Springer eBooks · doi:10.1007/978-0-387-72573-4_45 · Cited by 1
Herrera, F., Gonçalves, S. A., Branco‐Santos, J., & Outeiro, T. F. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00012-2
Schwartz, M., & Kipnis, J. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.11.021
Charakterisierung 14–3-3 homologer Gene und deren Bedeutung für die Parkinson'sche Erkrankung
Mosbacher, S., Holzmann, C., Hermann, K., Schwarz, N., Krüger, R., Ichimura, T., & Rieß, O. (2005) · Aktuelle Neurologie · doi:10.1055/s-2005-866634
Can Silent Ischemic Cerebral Lesions Affect Cognition of Parkinson's Disease Dementia?
Kang, I., Song, I., Lee, S., Kim, Y.-D., Cho, H.-J., Chung, S., & Yang, Y. (2013) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2013.12.3.72
A Case of Idiopathic Medulla Oblongata and Upper Cervical Cord Atrophy
Park, J. H., & Lee, S. (2006) · Journal of the Korean Neurological Association
da Silva, T. (2012) · Americanae (AECID Library)
Methylmercury and Alzheimer's Disease
Kintz, J. (2014)
45and Regenerative Autoimmunity in CNS Injury
Kipnis, J., & Schwartz, M. (2008)
González, A. J. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.59.2017.tde-10052017-144511
A Novel Method for Identifying Alzheimer’s Disease-related Proteins
Hu, Y., Zhang, J., Zhao, T., Cheng, L., & Zang, T. (2018) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2018.8621492
박정현, & Lee, S.-S. (2006)
Recent Development of Hybrids and Derivatives of Resveratrol in Neurodegenerative Diseases
Filippis, B. D., & Fantacuzzi, M. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815079098122010005
Shafi, O., Rajpar, R., Yaqoob, Ú., Rahman, I. A., Savanti, Madhwani, M., Haseeb, M., & Raveena (2024) · Research Square · doi:10.21203/rs.3.rs-3982517/v1
BindingDB (2023) · UC San Diego · doi:10.7270/q2445rhz
BindingDB Entry 50038080: Multi-target-directed ligands to combat neurodegenerative diseases.
BindingDB (2012) · UC San Diego · doi:10.7270/q25b039w
Metadata
- Authors
- Jellinger, K. A.
- Corresponding author
- Jellinger, K. A.
- ORCID
- Jellinger, K. A.
- Venue
- Journal of Neural Transmission. Supplementa
- Publisher
- Springer Vienna
- Published
- 2003
- Issue
- 65
- Pages
- 101-144
- ISSN
- 0303-6995 (ISSN-L)
- OpenAlex
- W48785815
- Cited by
- 126
- References
- 193
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 9 · 2013: 7 · 2012: 8
- FWCI
- 39.40
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Journal of neural transmission. Supplementum (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegeneration, neurodegenerative diseases, protein aggregation, protein inclusions, ubiquitin-proteasome system, oxidative stress, mitochondrial dysfunction, bioenergetics, neuroinflammation, programmed cell death, Alzheimer's disease, synucleinopathies, tauopathy, polyglutamine diseases, neuronal loss
- MeSH terms
- Animals, Inclusion Bodies, DNA, Mitochondrial, Humans, Iron, Mitochondria, Mutation, Nerve Degeneration, Nerve Tissue Proteins, Neuroglia, Neurons, Ubiquitins, Signal Transduction, Cell Death, Oxidative Stress, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review